Avantis Real Estate ETF (AVRE)
Live price chart, market sentiment, and community perspectives for Avantis Real Estate ETF (AMEX: AVRE).
Live price chart, market sentiment, and community perspectives for Avantis Real Estate ETF (AMEX: AVRE).
On our desk, we are closely tracking AVRE's low cost structure. With a net and gross expense ratio sitting flat at 0.17% and a turnover rate of 0%, it offers an impressively lean vehicle for capturing global real estate upside. However, sentiment across the institutional community remains somewhat guarded due to neutral ratings from Morningstar and Market Edge's recent caution regarding sell stops. While the 12.82% YTD NAV total return looks solid on paper, market participants are weighing whether macroeconomic interest rate fluctuations could cap further multiple expansion in the near term.
Looking at the structural composition of the fund, top holdings like Welltower (7.34%), Prologis (6.63%), and Equinix (5.34%) concentrate over 40% of total portfolio assets in a tight cluster of mega-cap REITs. For our risk management framework, this creates clear vulnerability to sector-specific headwinds. The prospectus explicitly warns about risks tied to property values, environmental contamination, zoning, and overbuilding. Even though the dividend yield sits around 3.34% with a 52-week trading range spanning from $42.98 to $49.72, investors must remain mindful that a focused real estate strategy inherently carries higher volatility than broad-market benchmarks.
During our quantitative screening protocols, I always examine how tightly price tracks net asset value. For AVRE, the daily metrics show a NAV of $48.48 against a market price of $48.58, with minor daily fluctuations around 0.34% to 0.39%. Historical data shows the fund managing a 16.0% annualized 1-year return and a 9.1% 3-year annualized return as of July 2026, slightly outperforming or matching the global real estate category average depending on the timeframe. When evaluating this ETF for client allocations, analysts must emphasize that past performance—such as its 2022 drawdown of over 24%—highlights its sensitivity to broader macroeconomic shocks.
Explore plasma cleansing, somatic organ swaps, and BCI.